Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

nasopharyngeal cancer

- PMLiVE

BeOne Medicines, BeOne Care Foundation and The Max Foundation renew partnership

This is to expand access to leukaemia treatment in low- and middle-income countries

- PMLiVE

BeOne Medicines appoints Kandeepan Ganeshalingam as Vice-President, Head of Medical Affairs, Europe

Ganeshalingam previously held senior leadership roles at Pfizer, Seagen, MSD and Roche

- PMLiVE

AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo

Rinvoq is the first and only systemic medication approved in the EU for NSV

- PMLiVE

CSL’s Privigen approved as measles treatment by European Commission

Cases of measles have been rising in Europe since 2023

- PMLiVE

Lilly’s early Alzheimer’s disease treatment approved in the EU

Marketing authorisation follows positive late-stage trial results

EU flag

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

The drug is already approved in the EU across three other multiple myeloma indications

- PMLiVE

J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

- PMLiVE

Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

- PMLiVE

Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

EU flag

EC approves SpringWorks Therapeutics’ Ezmekly to treat rare genetic disorder NF1

Neurofibromatosis type 1 affects an estimated 135,000 people in the EU

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links